Fred Hutchinson Cancer Center — Biomedical Watch V2

Traitements4programmes

Essais1liés

Publications12liées

SourceDBlocale

Traitements

4

Molécule	Indication / population	Phase	Objectif	Pays	Résultat
Anti-Thymocyte GlobulinThis phase II trial studies the side effects and how well carmustine, etoposide, cytarabine and melphalan together with antithymocyte globulin before a stem cell transplant works in treating patients with autoimmune neurologic disease that did not respond to previous therapy. In autoimmune neurological diseases, the patient's own immune system 'attacks' the nervous system which might include the brain/spinal cord and/or the peripheral nerves. Giving high-dose chemotherapy, including carmustine, etoposide, cytarabine, melphalan, and antithymocyte globulin, before a stem cell transplant weakens the immune system and may help stop the immune system from 'attacking' a patient's nervous system. When the patient's own (autologous) stem cells are infused into the patient they help the bone marrow make red blood cells, white blood cells, and platelets so the blood counts can improve.	Myasthénie	Phase 2	Thérapie cellulaire	United States	À vérifier
CarmustineThis phase II trial studies the side effects and how well carmustine, etoposide, cytarabine and melphalan together with antithymocyte globulin before a stem cell transplant works in treating patients with autoimmune neurologic disease that did not respond to previous therapy. In autoimmune neurological diseases, the patient's own immune system 'attacks' the nervous system which might include the brain/spinal cord and/or the peripheral nerves. Giving high-dose chemotherapy, including carmustine, etoposide, cytarabine, melphalan, and antithymocyte globulin, before a stem cell transplant weakens the immune system and may help stop the immune system from 'attacking' a patient's nervous system. When the patient's own (autologous) stem cells are infused into the patient they help the bone marrow make red blood cells, white blood cells, and platelets so the blood counts can improve.	Myasthénie	Phase 2	Thérapie cellulaire	United States	À vérifier
MelphalanThis phase II trial studies the side effects and how well carmustine, etoposide, cytarabine and melphalan together with antithymocyte globulin before a stem cell transplant works in treating patients with autoimmune neurologic disease that did not respond to previous therapy. In autoimmune neurological diseases, the patient's own immune system 'attacks' the nervous system which might include the brain/spinal cord and/or the peripheral nerves. Giving high-dose chemotherapy, including carmustine, etoposide, cytarabine, melphalan, and antithymocyte globulin, before a stem cell transplant weakens the immune system and may help stop the immune system from 'attacking' a patient's nervous system. When the patient's own (autologous) stem cells are infused into the patient they help the bone marrow make red blood cells, white blood cells, and platelets so the blood counts can improve.	Myasthénie	Phase 2	Thérapie cellulaire	United States	À vérifier
Anti-Thymocyte GlobulinThis phase II trial studies the side effects and how well carmustine, etoposide, cytarabine and melphalan together with antithymocyte globulin before a stem cell transplant works in treating patients with autoimmune neurologic disease that did not respond to previous therapy. In autoimmune neurological diseases, the patient's own immune system 'attacks' the nervous system which might include the brain/spinal cord and/or the peripheral nerves. Giving high-dose chemotherapy, including carmustine, etoposide, cytarabine, melphalan, and antithymocyte globulin, before a stem cell transplant weakens the immune system and may help stop the immune system from 'attacking' a patient's nervous system. When the patient's own (autologous) stem cells are infused into the patient they help the bone marrow make red blood cells, white blood cells, and platelets so the blood counts can improve.	Myasthénie	Phase 2	Thérapie cellulaire	United States	À vérifier

Essais cliniques

1

Molécule	Indication / population	Phase	NCT	Titre	Statut
Anti-Thymocyte Globulin	Myasthénie	Phase 2	NCT00716066	Autologous Stem Cell Transplant for Neurologic Autoimmune Diseases	ACTIVE_NOT_RECRUITING

Publications

12

Molécule	Indication / population	Titre	Journal	Date
Anti-Thymocyte Globulin		Chromosome 17p deletion in aplastic anaemia with paroxysmal nocturnal haemoglobinuria clone: a diagnostic challenge.	Journal of hematopathology
Anti-Thymocyte Globulin		Therapeutic-drug-monitoring-based ATG Targeted Dosing Strategy in Unmanipulated Haploidentical Haematopoietic Stem Cell Transplantation: a randomized, multicenter, phase 3 clinical trial.	Cancer letters
Carmustine		Atomic-scale insights into the interaction mechanism of carmustine on chitosan nanocarriers: A combined DFT and molecular dynamics study.	International journal of biological macromolecules
Carmustine		Multi-Omics Integration Identifies a Five-Gene Metabolic Signature With Experimental Validation in Clear Cell Renal Cell Carcinoma.	Cancer reports (Hoboken, N.J.)
Melphalan		Melphalan's Effect on Testicular Prepubertal Rats: Induction of Autophagy and Apoptosis, Modulated by the Potential of Chrysin.	Journal of medicinal food
Melphalan		Fludarabine, Busulfan, Thiotepa, and Melphalan: A Novel Low-Toxicity Myeloablative Conditioning Regimen for Haploidentical HSCT in Children and Adolescents Aged ≥7 Years With Transfusion-Dependent β-Thalassemia.	Pediatric blood & cancer
Melphalan		Self-assembled melphalan hydrogel with nitric oxide delivery for synergistic chemoimmunotherapy.	Journal of colloid and interface science
Carmustine		The Role of Cellular Glutathione Redox Cycle and Glutathione in the Regulation of Ileum Contractility.	International journal of molecular sciences
Carmustine		High-dose chemotherapy followed by autologous stem-cell transplantation versus non-myeloablative consolidation in primary CNS lymphoma (MATRix/IELSG43): a randomised phase 3 trial.	Lancet (London, England)
Carmustine		Triple-targeted artificial extracellular vesicles for enhanced glioma therapy via synergistic chemomagnetic penetration of the blood-brain barrier.	Colloids and surfaces. B, Biointerfaces
Melphalan		A computational study of perylene diimide as a potential nanocarrier for multiple drugs: adsorption, stability and release mechanisms.	Spectrochimica acta. Part A, Molecular and biomolecular spectroscopy
Melphalan		Anti-myeloma mechanisms of the selective NF-κB inhibitor QNZ.	Molecular therapy. Oncology